**HPTN 083**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC
- 4,570 cisgender men and transgender women who have sex with men

**Populations**
- Argentina, Brazil, Peru, South Africa, Thailand, U.S., Vietnam

**Locations**
- December 2016

**Start Date**
- Non-Inferiority of CAB LA to TDF/FTC
  - A non-inferiority study tests whether one drug works about the same as, but not worse than, another drug

**Study Design**
- **STEP 1**
  - 5 weeks of 2 daily oral pills
  - 1 active and 1 placebo

**Study Steps**
- **STEP 2**
  - Injections every 8 weeks and daily pills for up to 3 years

**Study Results**
- **STEP 3**
  - Daily oral pills for 48 weeks

The study showed **superiority** of CAB LA over oral TDF/FTC, meaning CAB LA worked better to prevent HIV infection in the population than oral TDF/FTC.

There was a **66%** reduction in HIV infections in study participants provided CAB compared to TDF/FTC.

**HPTN 084**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC
- 3,200 (projected) cisgender women

**Populations**
- Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, Zimbabwe

**Locations**
- November 2017

**Start Date**
- Superiority of CAB LA to TDF/FTC
  - A superiority study tests whether one drug works better than another drug

**Study Design**
- **STEP 1**
  - 5 weeks of 2 daily oral pills
  - 1 active and 1 placebo

**Study Steps**
- **STEP 2**
  - Injections every 8 weeks and daily pills for up to 3.5 years

**Study Results**
- **STEP 3**
  - Daily oral pills for 48 weeks

Results forthcoming upon study completion

= placebo